The 2023 EGFR Resisters/LUNGevity Award Program for EGFR-Positive Lung Cancer is now open for application submissions.
EGFR-positive lung cancer is a type of non-small cell lung cancer (NSCLC) in which the EGFR gene is mutated, promoting abnormal, unchecked cell growth. About 10%-15% of lung cancer patients have the EGFR mutation. While there are currently five FDA-approved targeted therapies to treat EGFR-positive lung cancer, the cancer inevitably recurs because the cells become resistant to the effects of the targeted therapies. Thus, there is a huge unmet need for additional treatment options for EGFR-positive lung cancer patients.
EGFR Resisters is a grassroots community of close to 4,000 EGFR-positive lung cancer patients and caregivers from 90+ countries, dedicated exclusively to improving outcomes for people with EGFR-positive lung cancer by changing EGFR-positive lung cancer into a manageable, chronic disease. The group uses the strength of its collaborations to drive important research questions and fund novel research and clinical trials. For more information about EGFR Resisters, please visit www.egfrcancer.org.
The research project(s) that will be funded is (are) expected to have a direct impact on the outcomes of patients with advanced EGFR-positive lung cancer, but innovative proposals that address other unmet needs in the EGFR-positive lung cancer space are also invited for submission. Please note that we are not accepting psychosocial research proposals as part of this RFA.
This award is open to researchers at both US and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution. All research funds will be disbursed through a US institution.
The award offers up to $100,000 per year for two years, for a maximum of $200,000.
An applicant may submit no more than two applications for this award.
A two-step application process will be used:
- A letter of intent (LOI), with a brief overview of the proposed project and biographical information
- A full application with an extended narrative about the project, as well as supporting information and documentation. Only a subset of applicants is invited to submit a full application following the review of the LOIs.
Reviewers are drawn from the LUNGevity Scientific Advisory Board and other EGFR experts.
Awardees have progress and financial reporting obligations during the award term.
Complete instructions and award details are included in the EGFR-Positive Lung Cancer Research Award Request for Applications. The application process will be managed via proposalCENTRAL.
2023 EGFR Resisters/LUNGevity Award Program for EGFR-Positive Lung Cancer Application Timeline
|LOIs due:||by February 27, 2023, 11:59 pm EST|
|Invitation to apply:||No earlier than March 31, 2023|
|Applications due:||May 8, 2023, 11:59 pm EDT|
|Award announcement:||Late summer 2023|
|Award start date:||November 1, 2023|